In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

Atherosclerotic renovascular disease (ARVD) reduces tissue perfusion and eventually leads to loss of kidney function with limited therapeutic options. Here we describe results of Phase 1a escalating dose clinical trial of autologous mesenchymal stem cell infusion for ARVD. Thirty-nine patients with...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Kidney Int
Main Authors: Abumoawad, Abdelrhman, Saad, Ahmed, Ferguson, Christopher M., Eirin, Alfonso, Herrmann, Sandra M., Hickson, LaTonya J., Goksu, Busra B., Bendel, Emily, Misra, Sanjay, Glockner, James, Dietz, Allan B., Lerman, Lilach O., Textor, Stephen C.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7284953/
https://ncbi.nlm.nih.gov/pubmed/32093917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.kint.2019.11.022
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares